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INTRODUCTION:  It is extremely  rare  for gallbladder  carcinoma  to  produce  granulocyte-colony  stimulating
factor  (G-CSF)  and  such  tumors  have a poor  prognosis.
PRESENTATION  OF  CASE:  A  67-year-old  man  was  admitted  with  continuous  fever.  Laboratory  tests  showed
a leukocyte  count  of  27,980/L,  serum  C-reactive  protein  (CRP)  of 9.2 mg/dL  and serum  G-CSF  of
225  pg/mL.  Imaging  revealed  an  irregular  gallbladder  mass  about  90 mm  in  diameter  with  peripheral
enhancement  that  also  involved  the  liver  and transverse  colon.  G-CSF  producing  gallbladder  carcinoma
was  diagnosed.  We  performed  cholecystectomy,  partial  resection  of segments  4  and  5 of  the  liver,  partial
resection of the transverse  colon,  and  gastrostomy.  Histopathological  examination  showed  gallbladder
carcinoma  (pT3,  pN0,  M0,  G2, and  pStage  IIIA  by  the  UICC  classiﬁcation,  version  7).  On  immunohistochem-
ical  staining,  tumor  cells  were  positive  for G-CSF.  The  leukocyte  count  was normalized  postoperatively
and  fever  subsided  immediately  after  surgery.  Two  months  later,  the  leukocyte  count  rose  to 56,820/L
and  metastases  to  the  liver  and  lymph  nodes  were  detected  by  CT.  Chemotherapy  (gemcitabine  plus
cisplatin)  was  started  and  the  leukocyte  count  was  normalized  after  the ﬁrst  course.  The  patient  has
continued  chemotherapy  and  has survived  for 16  months  postoperatively.
DISCUSSION:  G-CSF  producing  gallbladder  carcinoma  has  a  poor  prognosis  and most  patients  die within
12  months  of starting  therapy.  It  is  rare for patients  with  recurrence  to survive  for  16 months  after  surgery,
as  in  the present  case.
CONCLUSION: Multidisciplinary  therapy  (surgery  and  chemotherapy)  may  prolong  the  survival  of  patients
with G-CSF  producing  gallbladder  carcinoma,  especially  those  with  recurrence.
©  2016  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Production of granulocyte-colony stimulating factor (G-CSF) by
umor tissue was initially demonstrated by Robinson [1] in 1974
nd G-CSF-producing lung cancer was ﬁrst reported by Asano et al.
n 1977 [2]. The diagnostic criteria for G-CSF producing tumor
re as follows: (1) a very high leukocyte count, (2) an increased
erum level of G-CSF, (3) both the leukocyte count and G-CSF
ecrease after treatment, and (4) G-CSF production by tumor cells is
emonstrated.
∗ Corresponding author at: Department of Surgery, Tama-Nanbu Chiiki Hospital,
okyo Metropolitan Health and Medical Treatment Corporation, 2-1-2 Nakazawa,
ama, Tokyo 206-0036, Japan.
E-mail address: izumo@ige.twmu.ac.jp (W.  Izumo).
ttp://dx.doi.org/10.1016/j.ijscr.2016.02.037
210-2612/© 2016 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Carcinoma of the gallbladder rarely produces G-CSF and such
tumors generally have a poor prognosis. Here we  report a patient
with recurrence of G-CSF producing gallbladder carcinoma who has
survived for 16 months after surgery.
2. Presentation of case
A 67-year-old man  was  admitted to our hospital with con-
tinuous fever. He had received antibiotic therapy at his local
hospital for 3 months, but symptoms had not improved so he
was referred to our hospital. He had hypertension, but was a
nonsmoker and did not drink alcohol. He had not worked in the
printing industry. On examination, his temperature was 37.2 ◦C.
Laboratory tests showed a severe inﬂammatory response, with a
leukocyte count of 27,980/L and a serum C-reactive protein (CRP)
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. CT.
There is an irregular gallbladder mass about 90 mm in diameter with peripheral
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evel of 9.2 mg/dL Serum levels of alkaline phosphatase (ALP) and
-glutamyl transpeptidase (-GTP) were elevated to 488 U/L and
18 U/L, respectively. In addition, serum G-CSF was  elevated to
25 pg/mL and IL-6 was 52.9 pg/dL. Computed tomography (CT)
howed an irregular gallbladder mass about 90 mm in diameter
ith peripheral enhancement (Fig. 1). Magnetic resonance imag-
ng (MRI) also revealed an irregular mass about 90 mm in diameter
ith peripheral enhancement by gadolinium in the gallbladder. The
ass was low intensity on T1-weighted images and high inten-
ity on T2-weighted images (Fig. 2), and it extended to involve
he liver (segments 4 and 5) and the transverse colon. Magnetic
esonance cholangiopancreatography revealed that there was no
ancreaticobiliary maljunction. G-CSF producing gallbladder car-
inoma was diagnosed and the patient underwent resection of the
umor (cholecystectomy, partial resection of segments 4 and 5 of
he liver, and partial resection of the transverse colon) and gas-
rostomy. Histopathological examination of the resected specimen
howed gallbladder carcinoma, biliary type, adenocarcinoma (pT3,
N0, M0,  G2, and pStage IIIA by the UICC classiﬁcation, version 7).
he margins were healthy. Tumor cells were positive for G-CSF by
mmunohistochemical staining (Fig. 3). After surgery, the leukocyte
ount decreased rapidly to the normal range and fever subsided
mmediately. Two months later, the leukocyte count increased
o 56820/L and serum level of total bilirubin was  elevated to
.2 mg/dL. CT scans revealed liver and lymph node metastases
ith slight dilatation of the intrahepatic bile ducts. He under-
ent percutaneous transhepatic cholangio drainage, followed by
hemotherapy with gemcitabine (800 mg  per body) plus cisplatin
30 mg  per body) each administered on days 1 and 8, every 3
enhancement (arrows). The mass appears to invade the liver (segments 4 and 5)
and the transverse colon.
ig. 2. MRI  ﬁndings.
: Low intensity mass on a T1-weighted image (arrow).
: High intensity mass on a T2-weighted image (arrow).
, d: Irregular gallbladder mass about 90 mm in diameter with peripheral gadolinium enhancement (arrows).
ig. 3. Histopathological ﬁndings.
. Moderately differentiated tubular adenocarcinom
. Immunostaining of tumor cells was  positive for G-CSF.
a:  HE ×400, b: An immunohistochemistry with anti-G-CSF monoclonal antibodies ×400)
 –  OPEN  ACCESS
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eeks. After the ﬁrst course of chemotherapy, the leukocyte count
ecreased dramatically to the normal range. The patient has con-
inued chemotherapy and is still alive at 16 months after surgery
ith stable disease (revised RECIST guideline, version 1.1) [3]. The
atient provided written permission for publication of his case.
. Discussion
In our patient, gallbladder carcinoma was suspected from imag-
ng ﬁndings. Despite persistent fever and a very high leukocyte
ount, no microorganism was detected by blood culture and admin-
stration of antibiotics did not lead to improvement. These points
uggested G-CSF-producing gallbladder carcinoma and G-CSF was
ound to be elevated to 225 pg/ml.
(18)F-ﬂuorodeoxy-glucose positron emission tomography
FDG-PET) is a useful method for diagnosis of G-CSF producing
allbladder carcinoma. But it is difﬁcult to diagnosis of bone
etastasis. It is described that the diffuse FDG uptake present
n the spine and in fact, no bone metastases were detected [4].
ncreased FDG uptake by bone marrow was induced by incerased
n bone marrow metabolism and celularity in response to G-CSF.
5]. When the patients underwent FDG-PET, it is necessary for
aying attention to the diagnosis of bone metastasis.
Because his general condition was poor, it was  difﬁcult to per-
orm radical resection or chemotherapy, so we  performed limited
urgery to control inﬂammation. While G-CSF causes leukocyto-
is, it is thought that signs or symptoms of inﬂammation, such as
ever or elevation of CRP, are due to concomitant production of
nterleukin (IL)-6 by the tumor [6]. In our patient, IL-6 was  also
ncreased to52.9 pg/dL, which could explain the patient’s inﬂam-
atory symptoms.
We  searched PubMed using “Gallbladder carcinoma”, “G-CSF”,
nd “CSF” as key words and excluded duplicate reports; revealing
nly 11 patients including our case [4,7–15] (Table 1). They com-
rised 5 men  and 6 women  with a mean age of 66.2 years (range:
8–79 years). The mean tumor diameter was 100 (45–130) mm;
ean leukocyte count was 32,057 (9400–57,900)/L; and mean G-
SF level was 342.0 (46–1311). Tumor histology was moderately
ifferentiated tubular adenocarcinoma in 3 patients; poorly dif-
erentiated tubular adenocarcinoma in 1 patient; adenosquamous
arcinoma in 3 patients; squamous cell carcinoma in 1 patient;
nd undifferentiated carcinoma in 3 patients. Mean survival time
s 11.8 months. Five patients died within 6 months after surgery or
resentation and only 4 patients survived for ≥1 year. Unlike our
atient; the other patients who survived for ≥1 year underwent
urgery alone and did not experience recurrence. G-CSF-producing
allbladder carcinoma generally has a poor prognosis because the
umor is often poorly differentiated; G-CSF promotes the growth
f non-hematologic tumor cells [16]; and G-CSF-producing cells
ay  express G-CSF receptors allowing it to act as an autocrine
rowth factor promoting rapid tumor growth and/or metastasis
17]. In addition; persistent inﬂammation can compromise the gen-
ral condition; making it difﬁcult to perform chemotherapy.
As chemotherapy for unresectable biliary carcinoma, studies
erformed in the UK and Japan [18,19] have led to a Level 1
ecommendation for treatment with gemcitabine plus cisplatin
GC therapy) [20]. Accordingly, our patient received multidisci-
linary therapy with surgical resection and GC therapy. One of
he reasons for his relatively long survival may  be the tumor his-
ology, since he had moderately differentiated adenocarcinoma
hile many G-CSF-producing tumors are poorly differentiated. In
atients with G-CSF-producing gallbladder carcinoma, surgeons
ay  hesitate to operate because of inﬂammatory features, but this
ay  lead the patient’s general condition to deteriorate further.
n our patient, a good outcome may  have been achieved because Ta
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-CSF-producing gallbladder carcinoma was promptly diagnosed
nd resected, after which recurrence was suspected when the
eukocyte count increased again and chemotherapy was promptly
tarted following treatment of mild obstructive jaundice
. Conclusion
While G-CSF producing gallbladder carcinoma generally has a
oor prognosis, surgery to control inﬂammation should be per-
ormed as soon as possible and the leukocyte count should be
onitored to detect recurrence. If recurrence is found, the patient
hould immediately be offered chemotherapy. Multidisciplinary
herapy (surgery combined with chemotherapy) may  achieve
onger survival of patients with G-CSF producing gallbladder carci-
oma, especially after recurrence.
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